About Elixiron KY
Elixiron Immunotherapeutics, Inc. is a Taiwanese clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for a range of diseases, including vitiligo, Alzheimer's disease, hemophagocytic lymphohistiocytosis (HLH), and tumors. The company is based in Taipei, Taiwan. The company utilizes advanced translational medicine techniques and various drug modalities, such as biologics derived from phage display and single human B cell cloning platforms. Elixiron has two products in clinical research, both of which have received orphan drug designations from the FDA; one is currently in phase II clinical development. The company was founded by Hung Kai Chen. Hung Kai Chen has been the CEO since incorporation.
Related stocks
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on TPEX exchange Elixiron KY stocks are traded under the ticker 7871.
No, 7871 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 7871 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Elixiron KY stock right from TradingView charts — choose your broker and connect to your account.